Itrasia 100 Capsule contains Itraconazole 100 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various fungal infections, including aspergillosis, blastomycosis, histoplasmosis, and onychomycosis, as well as other systemic and superficial mycoses caused by susceptible fungi. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. The capsule formulation allows for oral administration with improved bioavailability when taken with food. Itrasia 100 is typically prescribed based on the severity and type of infection, with dosage adjustments required in special populations such as patients with hepatic impairment. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals and should be used cautiously in individuals with liver dysfunction. Potential adverse effects include gastrointestinal disturbances, headache, dizziness, and elevated liver enzymes. Drug interactions are significant due to itraconazole’s inhibition of cytochrome P450 enzymes; therefore, concomitant use with certain medications such as statins, benzodiazepines, and some antiepileptics should be avoided or closely monitored. Regular liver function tests and clinical monitoring are recommended during therapy to ensure safety and efficacy.